脂多糖结合蛋白和可溶性 CD14 作为卒中相关性肺炎的风险标志物。
Lipopolysaccharide binding protein and sCD14 as risk markers of stroke-associated pneumonia.
机构信息
Department of Neurology, Jagiellonian University Medical College, Krakow, Poland.
Department of Neurology, Jagiellonian University Medical College, Krakow, Poland.
出版信息
J Neuroimmunol. 2021 May 15;354:577532. doi: 10.1016/j.jneuroim.2021.577532. Epub 2021 Feb 27.
To determine the utility of lipopolysaccharide binding protein (LBP) and soluble CD14 (sCD14) as risk markers of stroke-associated pneumonia (SAP). We included 331 stroke patients. The plasma levels of LBP (median: 19.4 vs 15.3 μg/mL, P < 0.01) and sCD14 (median: 1.5 vs 1.4 μg/mL, P = 0.04) were elevated in SAP. In multivariate analysis, a higher level of LBP (OR: 1.09, 95%CI: 1.05-1.13), but not sCD14 (OR: 2.16, 0.94-4.97), was associated with SAP. The addition of LBP or sCD14 to the clinical model did not improve its discriminatory ability. Our results suggest the modest value of studied biomarkers for SAP prediction.
为了确定脂多糖结合蛋白（LBP）和可溶性 CD14（sCD14）作为卒中相关性肺炎（SAP）风险标志物的效用。我们纳入了 331 例卒中患者。SAP 患者的血浆 LBP（中位数：19.4 比 15.3μg/mL，P<0.01）和 sCD14（中位数：1.5 比 1.4μg/mL，P=0.04）水平升高。多变量分析显示，较高的 LBP 水平（OR：1.09，95%CI：1.05-1.13），而不是 sCD14（OR：2.16，0.94-4.97）与 SAP 相关。LBP 或 sCD14 的添加并未提高临床模型的判别能力。我们的结果表明，所研究的生物标志物对 SAP 预测的价值有限。
Zotero 插件